NantKwest

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CULVER CITY, Calif. & EL SEGUNDO, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. and NantKwest, Inc. (NASDAQ: NK), today announced the completion of their previously announced 100% stock-for-stock merger. This follows the satisfaction of all customary closing conditions, including approval of the merger by a majority of unaffiliated shareholders of NantKwest at its Special Meeting held on March 8, 2021. The combined company will operate under the name ImmunityBio, Inc. (“ImmunityBio”) and its share

ImmunityBio and NantKwest Complete Merger

The stock price of Nantkwest Inc (NASDAQ: NK) increased by over 15% pre-market. This is why it happened.

NK Stock Price Increases Over 15% Pre-Market: Why It Happened

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that its stockholders approved by the required vote each of the proposals related to the pending merger of NantKwest and ImmunityBio, Inc. presented at the special meeting of stockholders held earlier in the day, including approval of the merger by a majority of unaffiliated stockholders of NantKwest. Final voting results for NantKwest's special me

Stockholders of NantKwest Approve Merger With ImmunityBio

CULVER CITY & EL SEGUNDO, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc., a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced the first cohorts of their South Africa and U.S. COVID-19 vaccine trials have received their initial doses of the company's T-cell-based COVID-19 vaccine candidate, hAd5. This candidate is unique in targeting both the spike (S) and nucleocapsid (N) proteins of the SARS-CoV

ImmunityBio and NantKwest Begin Dosing Participants in Global Trials for Novel COVID-19 Vaccine; Subcutaneous Route in South Africa, Oral and Sublingual in the U.S.

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that leading independent proxy advisory firms Institutional Shareholder Services Inc. (“ISS”), Glass, Lewis & Co., LLC (“Glass Lewis”), and Egan-Jones Proxy Services (“Egan-Jones”) have recommended NantKwest stockholders vote “FOR” the pending merger with ImmunityBio. ISS concluded in its February 24, 2021 report: “Both NK and ImmunityBio have

All Three Independent Proxy Advisory Firms – ISS, Glass Lewis and Egan-Jones – Recommend NantKwest Stockholders Vote “FOR” the Pending Merger With ImmunityBio

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc., a privately-held immunotherapy company, today announced the appointment of John Brennan, former Central Intelligence Agency Director, and Wesley Clark, retired U.S. Army General, to the company's board of directors, effective immediately. With the appointment of Messrs. Brennan and Clark, the company's board expands to four directors, including Christobel Selecky, who was appointed to the board in August 2020, and Patrick Soon-Shiong, MD,

ImmunityBio Appoints John Brennan and Wesley Clark to Board of Directors

The stock price of Nantkwest Inc (NASDAQ: NK) is trading at over 12% pre-market as of 9:06 AM ET. This is why it happened.

NK Stock Price Increases Over 12% Pre-Market: Why It Happened

The FDA has signed off the expansion of Phase 1 testing of a COVID-19 vaccine candidate, developed by NantKwest Inc's (NASDAQ: NK) merger partner, ImmunityBio Inc, to include sublingual boosts (cohort C expansion) to the currently active multi-cohort trial of the subcutaneous version of the vaccine. The agency also authorized a second Phase 1 study that will examine the addition of an oral boost to the subcutaneous prime administration.

NantKwest/ImmunityBio's COVID-19 Vaccine Candidate To Be Tested For Oral And Sublingual Route Of Administration

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc., a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced they have received FDA authorization to expand Phase I testing of a bivalent hAd5 T-cell COVID-19 vaccine. The FDA authorized the expansion of a currently active multi-cohort trial of the subcutaneous version of the vaccine in order to study the addition of sublingual boosts. The FDA a

ImmunityBio and NantKwest Announce FDA Authorization to Study hAd5 T-Cell COVID-19 Vaccine for Combination of Subcutaneous, Oral and Sublingual Boost to Induce T-Cell, Mucosal, and Antibody Immunity

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of NantKwest, Inc. (NasdaqGS: NK) with ImmunityBio, Inc. pursuant to which NantKwest shareholders will end up owning just 28% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company. If you believe that th

NANTKWEST INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of NantKwest, Inc. - NK

BERWYN, Pa., Jan. 21, 2021 /PRNewswire/ -- RM LAW, P.C. is investigating potential claims against the board of directors of NantKwest, Inc. ("NantKwest" or the "Company") (NASDAQ: NK) concerning possible breaches of fiduciary duty and other violations of law related to the Company's...

RM LAW Announces Investigation of NantKwest, Inc.

NEW YORK--(BUSINESS WIRE)--Labaton Sucharow, a nationally ranked and award-winning shareholder rights law firm, is investigating potential securities violations and breach of fiduciary duty against cellular therapies company NantKwest, Inc. (NASDAQ: NK) in connection with its acquisition of ImmunityBio, a privately held company. If you currently own shares of NantKwest and want to receive additional information and protect your investments free of charge, please contact David J. Schwartz using

INVESTIGATION ALERT: Nationally Ranked Shareholder Rights Law Firm Labaton Sucharow is Investigating NantKwest, Inc. (NASDAQ: NK) for Potential Securities Violations and Breach of Fiduciary Duty

PHILADELPHIA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating NantKwest, Inc. (“NantKwest”) (NASDAQ: NK) on behalf of the company's shareholders.

NK INVESTOR ALERT: Kaskela Law LLC Announces Stockholder Investigation of NantKwest, Inc.

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that NantKwest, Inc. (NASDAQ: NK) (“NantKwest”) and ImmunityBio, Inc. (“ImmunityBio”) have announced that their ongoing Phase 2 clinical trials of a novel combination immunotherapy – which include CytRx's licensed drug aldoxorubicin – for locally advanced o

CytRx Highlights Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Patients

NantKwest and ImmunityBio announced they are preparing to merge to create a juggernaut immunotherapy and cell therapy company. Now, NantKwest investors will have ownership of ImmunityBio's impressive pipeline. As the COVID-19 pandemic accelerates and new variants emerge, health agencies are going to need more options to vaccinate and treat the world's population.

NantKwest: Taking A Deeper Dive Into Their COVID-19 Vaccine Efforts As Deaths Spike And New Variants Evolve

Clinical-stage immunotherapy company Nantkwest Inc (NASDAQ: NK) reports positive interim data on survival rates in the Metastatic Pancreatic Cancer QUILT 88 trial on Wednesday. What Happened: Nantkwest said that early interim results of its PD-L1 t-haNK protocols showing median survival rates more than doubled that of the historical rate in patients with advanced metastatic pancreatic cancer for which no other FDA-approved treatment exists.

NantKwest Reports Positive Interim Data In Pancreatic Cancer Trials, Stock Soars

EL SEGUNDO & CULVER CITY, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, Inc., a privately-held immunotherapy company, today announced early interim results of its PD-L1 t-haNK protocols showing median survival rates more than doubled that of the historic rate in patients with advanced metastatic pancreatic cancer for which no other FDA-approved treatment exists. These trials, which were based on the orig

NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Dr. Patrick Soon-Shiong M.D., Executive Chairman of the Board of Directors, will participate in the 39th Annual J.P. Morgan Healthcare Conference. He will make a formal presentation and answer questions at 5:20 a.m. Pacific Time (8:20 a.m. Eastern Time) on Wednesday, January 13, 2021. Dr. Soon-Shiong will discuss NantKwest's previously announc

NantKwest Executive Chairman Dr. Patrick Soon-Shiong to Present at 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021

"Natural killer" (or NK) cancer therapies are hot right now. Here are two stocks that are early leaders in the field -- one is a buy, and the other one is not.

Here's a Cancer-Killing Stock to Buy for 2021

PHILADELPHIA, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating NantKwest, Inc. (“NantKwest”) (NASDAQ: NK) on behalf of the company's shareholders.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of NantKwest, Inc. (NK) and Encourages Shareholders to Contact the Firm

WILMINGTON, Del., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against the Board of Directors of NantKwest, Inc. (NASDAQGS: NK) (“NantKwest” or the “Company”) relating to the sale of the Company to ImmunityBio, a privately-held company founded and controlled by Dr. Patrick Soon-Shiong, NantKwest's controlling stockholder who currently controls and owns approximately 64% of NantKwest. The two parties have announced that they reached an agreement in principle pursuant to which ImmunityBio will enter into a reverse merger with NantKwest. Under the terms of the agreement, ImmunityBio shareholders will receive a fixed exchange ratio of 0.8190 shares of NantKwest for each share of ImmunityBio owned. Upon completion of the merger, NantKwest shareholder will only own approximately 28% of the combined company.

NANTKWEST (NK) SHAREHOLDER ALERT - Andrews & Springer LLC Is Seeking More Cash for Shareholders of NantKwest, Inc.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of NantKwest, Inc. (NASDAQ:NK) and ImmunityBio is fair to NantKwest shareholders. Under the terms of the agreement, ImmunityBio shareholders will receive a fixed exchange ratio of 0.8190 shares of NantKwest for each share of ImmunityBio owned. Upon completion of the transaction, ImmunityBio shareholders will own approximately 72% of the combined company and NantKwest shareholders

NantKwest Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of NantKwest, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – NK

NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating NantKwest, Inc. ("NK" or the "Company") (NK) relating to its...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of NantKwest, Inc. - NK

WILMINGTON, Del., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating NantKwest, Inc. (“NantKwest”) (NASDAQ GS: NK) regarding possible breaches of fiduciary duties and other violations of law related to NantKwest's agreement to merge with ImmunityBio, Inc.

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of NantKwest, Inc. Merger

The stock price of NantKwest Inc (NASDAQ: NK) increased by 9.93% on December 22. This is why it happened.

News for NantKwest Stock (NK)